• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment

Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment

by Truveta Research | May 9, 2023 | Research, Research Insights

This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes.   Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
ISPOR 2023: Presenting Truveta Research’s recent type 2 diabetes findings

ISPOR 2023: Presenting Truveta Research’s recent type 2 diabetes findings

by Truveta staff | May 4, 2023 | News

This post is authored by Tricia Rodriguez, senior applied scientist, Truveta Research. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is gearing up for a fantastic event, slated for May 7-10, 2023, in Boston. As an applied scientist with...

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice